Mauricette C. Michallet

Pierre Bénite Université Claude Bernard Lyon I Faculté De Médecine Lyon Est
Lyon, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 238 publications

Deferasirox 6 months after allo-HSCT in AML/MDS: a prospective propensity-matched study.

Deferasirox 6 months after allo-HSCT in AML/MDS: a prospective propensity-matched study.

Journal: Blood advances

Published: October 27, 2025

Effect of Deferasirox Six Months after allo-HSCT on AML/MDS Outcomes: a Propensity-Score Matched Study.

Effect of Deferasirox Six Months after allo-HSCT on AML/MDS Outcomes: a Propensity-Score Matched Study.

Journal: Blood advances

Published: October 27, 2025

Prognostic impact of measurable residual disease in AML patients treated frontline with azacitidine and venetoclax: results from the French VENAURA registry.

Prognostic impact of measurable residual disease in AML patients treated frontline with azacitidine and venetoclax: results from the French VENAURA registry.

Journal: Leukemia

Published: October 25, 2025

Individualized physical activity program for older adults undergoing chemotherapy for hematologic malignancies.

Individualized physical activity program for older adults undergoing chemotherapy for hematologic malignancies.

Journal: Journal of geriatric oncology

Published: October 10, 2025

Allogeneic hematopoietic stem cell transplantation after azacitidine and venetoclax salvage in relapsed/refractory AML: a multicenter real-world study by the French AURAML group.

Allogeneic hematopoietic stem cell transplantation after azacitidine and venetoclax salvage in relapsed/refractory AML: a multicenter real-world study by the French AURAML group.

Journal: Bone marrow transplantation

Published: October 01, 2025

Presentation of PASCA, a day hospital dedicated to multidisciplinary cancer survivorship assessment

Presentation of PASCA, a day hospital dedicated to multidisciplinary cancer survivorship assessment

Journal: Bulletin du cancer

Published: August 26, 2025

HLA diversity is associated with TKI response and treatment-free remission in chronic myeloid leukemia.

HLA diversity is associated with TKI response and treatment-free remission in chronic myeloid leukemia.

Journal: HemaSphere

Published: July 21, 2025

Five-year molecular response and overall survival with first- and second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase: a prospective, observational study - SIMPLICITY.

Five-year molecular response and overall survival with first- and second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase: a prospective, observational study - SIMPLICITY.

Journal: Leukemia & lymphoma

Published: June 23, 2025

Real-world treatment and long-term outcomes after autologous stem cell transplantation in first line for myeloma in France and Algeria before the daratumumab era.

Real-world treatment and long-term outcomes after autologous stem cell transplantation in first line for myeloma in France and Algeria before the daratumumab era.

Journal: Current research in translational medicine

Published: February 25, 2025

Detection of potential complications in cancer survivors after chemotherapy and development of a regional care network: the PASCA feasibility study.

Detection of potential complications in cancer survivors after chemotherapy and development of a regional care network: the PASCA feasibility study.

Journal: Frontiers in medicine

Published: July 26, 2024

An Integrated Cancer Prevention Strategy: the Viewpoint of the Leon Berard Comprehensive Cancer Center Lyon, France.

An Integrated Cancer Prevention Strategy: the Viewpoint of the Leon Berard Comprehensive Cancer Center Lyon, France.

Journal: Cancer prevention research (Philadelphia, Pa.)

Published: September 30, 2023

Second line extracorporeal photopheresis for cortico-resistant acute and chronic GVHD after allogeneic hematopoietic cell transplantation for hematological malignancies: Long-term results from a real-life study.

Second line extracorporeal photopheresis for cortico-resistant acute and chronic GVHD after allogeneic hematopoietic cell transplantation for hematological malignancies: Long-term results from a real-life study.

Journal: Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis

Published: September 13, 2023

Showing 1-12 of 238

Last Updated: 09/26/2026